Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial

NCT07699770 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT07699770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial
Lead sponsor
Tang-Du Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
June 15, 2026
Completion date
December 31, 2027
Enrollment
110 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorders (nmosd), neuropathic pain